The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report.
In a Jan. 2 research note, ROTH Capital Partners analyst Jonathan Aschoff reported that he is assuming coverage on VBL Therapeutics (VBLT:NASDAQ) and changing its target price to $5 per share. The stock is now trading at around $1.26 per share.
Also, Aschoff highlighted that 2020 for VBL Therapeutics will be "catalyst rich" with respect to its lead drug candidate, VB-111, which it is developing for three initial oncology indications: recurrent, platinum-resistant ovarian cancer, glioblastoma multiforme and colon cancer.
Specifically, two interim data readouts are expected in Q1/20 and Q4/20 from VBL's Phase 3 ovarian cancer trial. The analyses of those data "will evaluate efficacy and futility, as well as serve as an indication that the trial is progressing like the successful prior 21-patient Phase 1/2 ovarian cancer trial that was presented at the annual meeting of the American Society of Clinical Oncology in 2019," Aschoff explained.
In addition, the analyst pointed out, two further studies involving VB-111 are expected to be launched in Q1/20. One is a randomized, controlled investigator-sponsored trial in recurrent glioblastoma multiforme, for which complete results are anticipated in Q1/21.
The other is a National Cancer Institute-sponsored, colon cancer trial in which VB-111 will be evaluated in combination with the checkpoint inhibitor Opdivo. An initial data readout for that study is anticipated in Q4/20. "The NCI trial is of particular interest because it may show synergy between VB-111 and widely used immunotherapy," Aschoff indicated.
Two further catalysts expected in late 2020 are investigational new drug application filings by VBL Therapeutics for two of its monoclonal antibodies (mAb) in development: its traditional anti-inflammatory mAb VB-601 and its bispecific anticancer mAb VB-611. These mAbs target MOSPD2, a protein the biopharma has characterized comprehensively. "We believe there is genuine potential outside interest in drugs having this mechanism of action," commented Aschoff.
He concluded that ROTH's $5 per share, 12-month price target on VBL Therapeutics is wholly based on the company's commercial success in the U.S. of VB-111 in ovarian cancer, primarily the recurrent, platinum resistant kind, and in recurrent glioblastoma multiforme. ROTH has a Buy rating on the biopharma.
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures from ROTH Capital Partners, VBL Therapeutics, Company Note, January 2, 2020
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
ROTH makes a market in shares of VBL Therapeutics and as such, buys and sells from customers on a principal basis.
Shares of VBL Therapeutics may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.
Within the last twelve months, ROTH has received compensation for non-investment banking securities-related services from VBL Therapeutics.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.